References
Laurenti L, Tarnani M, Efremov DG, Chiusolo P, De Padua L, Sica S et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007, in press.
Karlsson C, Hansson H, Celsing F, Lundin J . Treatment of severe refractory autoimmune hemolytic anemia (AIHA) in B-cell chronic lymphocytic leukemia (B-CLL) with alemtuzumab humanized CD52 monoclonal antibody. Leukemia 2007; 21: 511–514.
Hale G, Rebello P, Brettman L, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lundin, J. Reply to ‘Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia’ by Dr Laurenti et al.. Leukemia 21, 1821 (2007). https://doi.org/10.1038/sj.leu.2404704
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404704
- Springer Nature Limited